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diastolic blood pressure were 130.14 mmHg and 73.48 mmHg respectively. Inci-
dences of co-morbidities was as follow: ischemic heart disease in 49.3%, arterial
hypertension in 34.12%, diabetes in 28.03%, atrial fibrillation in 9.94% and renal
insufficiency in 8.55%. In 60.7% of patients we measured blood pressure below
140/90 mmHg (mean 116.94/70.4 mmHg) while in 39.9% blood pressure was
higher than 140/90 mmHg (mean 159.89/101.14 mmHg). Average blood pressure
differed significantly (p<0.001) between two groups. There was a significantly dif-
ference on prescript of ACE inhibitors (76.09% vs 57.33%), beta blockers (70.3%
vs 52.78%), calcium channel blockers (4.69% vs 17.02%) and digoxine (2.94% vs
1.68%). Patients with lowest blood pressure were less often treated with furo-
semide (28.33% vs 45.63%, p<0.05) but more often with spironolactone (55.78%
vs 32.37%, p<0.05).
Conclusions: The management of blood pressure in chronic heart failure is
very important and due to an adequate and optimal pharmacological treatment.
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Purpose: Hyperuricemia could be a valid prognostic marker and useful for
metabolic, hemodynamic, and functional staging in chronic heart failure. hyper-
uricemia is associated with deleterious effects on endothelial dysfunction, oxida-
tive metabolism, platelet adhesiveness, hemorheology, and aggregation
Methods: The purpose of this study was to determine association between
hyperuricemia and prognosis in 1509 patients with chronic heart failure,
during median follow-up of 32 months. Chi2 test was used, a difference was
statistically considered significant if p<0.05.
Results: The prevalence of hyperuricemia was 10.73% (162), the mean age
was 64.62 years (37-100) with a male predominance (64.81%). The mean
ejection fraction was 32.47%. Thirty eight percent patients have hypertension
and 21.6% have diabetes. There was a correlation between hyperuricemia and
severity of heart failure compared with normouricemia evaluated by: NYHA
functional class, [75,72% patients with hyperuricemia were in class II vs
61.03% for normouricemia (p= 0.0093), 35,69% in class III vs 25.03%
(p=0.0095) and 4.98% in class IV vs 2.09% (p=0.0091)], renal dysfunction:
mean creatinine was at 16.25 for hyperuricemia vs 11 mg per litr for normou-
ricemia, use of diuretics 61.11% vs 40.46% (p=0.0059), congestive heart
failure in 24.07% vs 12.04% (p=0.0086)
Conclusions: High serum uric acid levels are a strong, independent marker
of impaired prognosis in patients with chronic heart failure
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Background: Heart failure (HF) patients are particularly susceptible to
electrolyte abnormalities and especially to hyperkalemia. Potassium (K) bal-
ance may be lost both through the neurohormonal mechanisms and through
the drugs used in the treatment of this illness. Both hypokalaemia and hyper-
kalaemia are associated with increased mortality, mainly due to a higher risk
of potentially fatal arrhythmia.
Our goal was to explore the incidence and predictors of hyperkalemia in a
broad population of heart failure patients.
Methods: This was a retrospective study of 1371 consecutive patients
admitted to the therapeutic unit for heart failure between May 2006 and Sep-
tember 2010. Patients on dialysis and those with an estimated glomular filtra-
tion rate (GFR)<10ml/min/1,73m² were excluded. Complete history on
admission, age, sex, body weight, physical findings, comorbidities, and labo-
ratory information were collected.
Results: The mean age of our population was 64.4 years (16-100), with a male
predominance (64.6%). In 18 patients (1.3%) K was <3.0 mmol/L, and in 424
patients (30.9%) K was >5.0 mmol/L. Independent of treatment assignment,
patients at highest risk for hyperkalemia were those with age 75 years (28.5%),
diabetes (33.9%), male gender (25.5%), high potassium at baseline (24.5%), renal
dysfunction (44.5%) (identified by creatinine 2 mg/dl or GFR 30 ml/min/1.73m²),
symptomatic HF (28.1%) and those receiving therapy with angiotensin-converting
enzyme (ACE) inhibitors (25.3%) or spironolactone (27.2%).
Conclusion: Changes in potassium ion may cause life-threatening arrhyth-
mias. The risk of hyperkalemia is increased in symptomatic heart failure
patients with comorbidities or combined renin-angiotensin-aldosterone system
(RAAS) blockade. A favorable balance of benefit and risk requires clinical
vigilance and closer laboratory monitoring, particularly among these patients.
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Background: Chronic Heart failure (CHF) has a poor prognosis. Most of right
ventricular (RV) echocardiographic variables measure only basal or annular RV
function. Global 2D strain, is used to detect the first signs of LV dysfunction. Our
hypothesis was that RV-2Dstrain, allowing to measure basal to apical RV lateral
wall systolic function, was lower in CHF than in controls and was a better pre-
dictor of cardiac events in CHF than other RV echo-variables.
Methods: 43 controls and 118 chronic heart failure patients with sinus
rhythm, optimal medication and stabilized at east for one month (CHF) were
prospectively enrolled from November 2005 to April 2008 in our CHF clinic.
All patients had a clinical, biological and echocardiographic assessment. 2D
RV strain and four chamber LV strain, left ventricle and left atria dimensions,
diastolic LV function, tricuspid annular plane excursion, peak systolic velocity
of the tricuspid annular using tissue Doppler imaging were assessed. The pri-
mary endpoint was death or urgent transplantation or ventricular assist device
or an acute heart failure episode.
Results: RV-2Dstrain was measurable in 39 controls (57.5±17.2 years,
50% men) with a median and 95% CI of: –30% (–39%; –20%). RV-2Dstrain
was measurable in 104 CHF, their age and left ventricular ejection fraction
mean +/– SD were 57.0±10.9 years and 28.8±8.2%. 80 % were men. RV-
2Dstrain mean and 95%CI in CHF was –19%(–34%; –9%). Prevalence of RV
dysfunction was 52% in CHF if –20% was used as threshold. During a mean+/
– SD follow-up of 37+/–14 months for the patients without events. 57 patients
reached the primary endpoint. On Cox proportional hazards multivariate anal-
ysis only RV-2Dstrain and logBNP were independent predictor of outcome.
The threshold of RV-2Dstrain defined using ROC curve was –21%. Patients
with RV-2Dstrain >–21% had the worse prognosis (X2-log-Rank test=14,
p<0.0001) than patient with RV-2Dstrain <–21%.
Conclusion: RV 2D strain is a strong independent predictor of outcome in
HF and appears to be superior to the other RV or LV systolic echocardio-
graphic variables.
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Biochemical marker testing has revolutionized the approach to diag-
nosis and management of heart failure (HF). Natriuretic peptides are rou-
tinely used, nevertheless better biomarkers are needed to improve
diagnosis and guide therapy. Applying proteomics to clinical samples from
patients with acute heart failure (AHF), Quiescin Q6 (QSOX1) emerged as
a promising marker to differentiate dyspnea caused by acute decompensated
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heart failure (ADHF) from other syndroms. Our aim was to get insights
into the pathophysiological conditions leading to altered expression of
QSOX1 through the use of HF model rats.
Methods: Using thoracic aortic constriction (TAC), a model that rap-
idly progresses from cardiac hypertrophy to AHF as shown by echocardio-
graphic and anatomical data, we analyzed the level of QSOX1 transcript.
mRNA expression was measured by RT-qPCR and that of proteins by
Western-Blot.
Results: Qsox1 mRNAs were up-regulated (x4; p<0.05) in the LV of TAC
animals at 12 days post surgery, together with depressed LV shortening fraction.
BNP mRNAs show an earlier rise (x2.1; p<0.05), at 4.5 days post surgery.
QSOX1 mRNA level was also up-regulated in the left atria (x2.1; p<0.05), 56
days after surgery, the time when LA hypertrophy is maximum and AHF is truly
developed. Of note all other tissues, so far tested (liver, kidney, skeletal muscle,
lung), expressed similar QSOX1 level whatever groups and time after surgery.
Furthermore unaltered QSOX1 expression was noticed in chronic HF car-
diac tissues (with ejection fraction <30%) whereas BNP was elevated (x2.8;
p= 0.03). Thus data in human plasma that links QSOX1 to the AHF pathogen-
esis are corroborated in the animal models showing QSOX1 induction in both
the LV and the LA in AHF rats associated with severe pulmonary congestion.
Conclusion: Studies in rat models show that QSOX1 expression is induced
as a result of pressure overload leading to heart failure. We propose QSOX1
as new marker for aid in diagnosis of AHF patients.
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Beta-blocker use improves left ventricular ejection fraction (LVEF) in
patients with heart failure. A similar effect of beta-blockers on right ventric-
ular function has been proposed, although the effect of Bisoprolol on right
ventricular function has not been assessed.
This study investigated the short-term effect of Bisoprolol on right ventricular
function in chronic heart failure patients. A cohort of 60 heart failure patients who
were not taking beta-blockers at baseline was studied prospectively. Right ventric-
ular ejection fraction (RVEF) and LVEF were measured at both baseline and
6 months by echocardiography. Various parameters of the right ventricular func-
tion were measured: Simpson RVEF, surface shortening fraction, right ventricular
outflow tract (RVOT %), TAPSE (mm), S' wave with tissue doppler (S' dti cm/s),
and the Tei index. The threshold of significativity was fixed at 5%. Bisoprolol was
up titred during six months by a preestablished protocol to a target dose of 10 mg/
Od. Mean age was 65.7±16.3 years. Baseline RVEF was 25.6±5.2% and baseline
LVEF was 20.8±6.4%. Mean Bisoprolol dose reached was 25±12.5 mg daily. At
12 months, RVEF was significantly increased by 7.5% (95% confidence interval,
3.9-10.2; p=0.0001) and LVEF also increased significantly by 7.5% (95% confi-
dence interval, 4.0%-11.9%; p=0.0003). All the parameters of the right ventricular
function were significantly improved:
TAPSE (15.5 vs 12.7; p=0.078), Doppler S’dti cm/s (10.7 vs 8.2; p=0.002),
tei index (54.10vs 81.45; p=0.0008, RVOT% (27.1 vs 19.3; p=0.036), dp/dt
RV (721vs 505; p=0.05).
The efficacy and good tolerance of bisoprolol is demonstrated in this study
on chronic heart failure with right ventricular dysfunction when administered
in a precise pattern
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Purpose: Emergency extra-corporeal membrane oxygenation (ECMO)
implantation for severe cardiac shock or refractory cardiac arrest (under car-
diac massage), conducted in hospitals with on-site cardiac surgical facilities,
has been reported as both safe and effective. We report the feasibility, in-hos-
pital complications and outcomes of ECMO implantation, in a local hospital
without on-site cardiac surgical facilities.
Methods: This single-centre, prospective, consecutive cohort study
involved 50 pts who had ECMO implantation (2006-2010). Of these pts, 26
were in severe cardiac shock and 24 in refractory cardiac arrest. Implantations
were done by an interventional cardiologist team available 24/7, and in collab-
oration with the nearest cardiac surgical institution, located 100 km away, to
which patients were transferred subsequently.
Results: Stable ECMO implantation was achieved in 89% of pts in severe
cardiac shock and in 79% in refractory cardiac arrest. In-hospital complica-
tions occurred in 20/23 pts in cardiac shock and 13/23 were discharged alive.
In-hospital complications occurred in 18/19 pts in refractory cardiac arrest and
1/19 was discharged alive.
Conclusion: In a hospital with no cardiac surgical facilities, rates of
implantation failure, initial complications, and hospital outcomes in pts who
had ECMO implantation for severe cardiac shock or refractory cardiac arrest
were concordant with previous reports from hospitals with cardiac surgical
facilities. We observed a low rate of survival among implanted pts in refrac-
tory cardiac arrest.
Table – Outcomes for patients in severe cardiac shock or refractory cardiac 
arrest undergoing ECMO implantation
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Chemoreflex-mediated sympathetic activation contributes to both initiation
and progression of chronic heart failure (CHF).
Aims: to study the direct role of increased peripheral chemosensitivity in
reducing sympathetic baroreflex function in CHF patients.
Methods and results: we compared sympathetic baroreflex function assessed
by the slope of the relationship between muscle sympathetic nerve activity
(MSNA) and diastolic blood pressure in CHF patients with augmented (n=18) and
normal (n=20) peripheral chemosensitivity. Using a double-blind, randomized,
vehicle-controlled study we examined the effect of chemoreflex deactivation (by
breathing 100% oxygen for 15 min) on sympathetic baroreflex function in CHF
patients with elevated and with normal chemosensitivity. Baseline MSNA was
elevated (60.6±3.2 versus 48.9±3.7 bursts/min; P<0.05) and sympathetic barore-
flex function impaired (3.06±0.55 vs 5.51±0.69 %bursts/mmHg, P<0.05) in CHF
patients with augmented peripheral chemosensitivity compared with controls.
Administration of 100% oxygen led to a significant decrease in MSNA (from
60.5±3.2 to 52.6±3.2 bursts/min; P<0.001) and increase in sympathetic baroreflex
(from 2.95±0.56 to 6.18±0.77; P<0.001) in CHF patients with enhanced chemore-
flex sensitivity. In contrast, neither room air nor 100% oxygen changed MSNA,
hemodynamics or sympathetic baroreflex function in CHF patients with normal
chemosensitivity.
Conclusion: we report for the first time that increased peripheral chemore-
flex sensitivity directly decrease sympathetic baroreflex function in CHF
patients. This interaction contributes to sympathetic overactivity and blunted
sympathetic baroreflex function of CHF patients and may explain how
chemoreceptors contribute to the bad prognosis of CHF patients.
Outcome Severe cardiac 
shock 
(n=26) 
Refractory cardiac 
arrest 
(n=24) 
Stable EMCO implantation achieved (%) 23 (89) 19 (79) 
Median duration of external cardiac 
massage, min (IQR)
– 90 (43-57) 
In-hospital complications (%) 20/23 (87) 18/19 (95) 
In-hospital death 10/23 (44) 18/19 (95)
